These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 25016061)

  • 1. Both sunitinib and sorafenib are effective treatments for pheochromocytoma in a xenograft model.
    Denorme M; Yon L; Roux C; Gonzalez BJ; Baudin E; Anouar Y; Dubessy C
    Cancer Lett; 2014 Oct; 352(2):236-44. PubMed ID: 25016061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib.
    Fiorio Pla A; Brossa A; Bernardini M; Genova T; Grolez G; Villers A; Leroy X; Prevarskaya N; Gkika D; Bussolati B
    BMC Cancer; 2014 Dec; 14():939. PubMed ID: 25494980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer.
    Rosa R; Damiano V; Nappi L; Formisano L; Massari F; Scarpa A; Martignoni G; Bianco R; Tortora G
    Br J Cancer; 2013 Aug; 109(3):686-93. PubMed ID: 23839492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiangiogenic therapy promoted metastasis of hepatocellular carcinoma by suppressing host-derived interleukin-12b in mouse models.
    Zhu XD; Sun HC; Xu HX; Kong LQ; Chai ZT; Lu L; Zhang JB; Gao DM; Wang WQ; Zhang W; Zhuang PY; Wu WZ; Wang L; Tang ZY
    Angiogenesis; 2013 Oct; 16(4):809-20. PubMed ID: 23716000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas.
    Cassol CA; Winer D; Liu W; Guo M; Ezzat S; Asa SL
    Mod Pathol; 2014 Aug; 27(8):1050-62. PubMed ID: 24390213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon alpha and rapamycin inhibit the growth of pheochromocytoma PC12 line in vitro.
    Motylewska E; Lawnicka H; Kowalewicz-Kulbat M; Sicinska P; Niedziela A; Melen-Mucha G; Stepien H
    Endokrynol Pol; 2013; 64(5):368-74. PubMed ID: 24186594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
    Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
    Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of autophagy enhances sunitinib-induced cytotoxicity in rat pheochromocytoma PC12 cells.
    Ikeda T; Ishii KA; Saito Y; Miura M; Otagiri A; Kawakami Y; Shimano H; Hara H; Takekoshi K
    J Pharmacol Sci; 2013; 121(1):67-73. PubMed ID: 23269235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Pazopanib, Sunitinib, and Sorafenib, Anti-VEGF Agents, on the Growth of Experimental Endometriosis in Rats.
    Yildiz C; Kacan T; Akkar OB; Karakus S; Kacan SB; Ozer H; Cetin A
    Reprod Sci; 2015 Nov; 22(11):1445-51. PubMed ID: 25963915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leukocyte trafficking is not affected by multikinase inhibitors sunitinib or sorafenib in mice.
    Laurila JP; Laukkanen MO; Joensuu H; Salmi M; Jalkanen S
    Int J Cancer; 2016 Nov; 139(10):2270-6. PubMed ID: 27459381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct antifibrogenic effects of erlotinib, sunitinib and sorafenib on rat pancreatic stellate cells.
    Elsner A; Lange F; Fitzner B; Heuschkel M; Krause BJ; Jaster R
    World J Gastroenterol; 2014 Jun; 20(24):7914-25. PubMed ID: 24976727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma.
    Randrup Hansen C; Grimm D; Bauer J; Wehland M; Magnusson NE
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential biomarkers for the therapeutic efficacy of sorafenib, sunitinib and everolimus.
    Nakai Y; Miyake M; Morizawa Y; Hori S; Tatsumi Y; Anai S; Onishi S; Tanaka N; Fujimoto K
    Oncol Rep; 2017 Jan; 37(1):227-234. PubMed ID: 27840968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
    Erdem L; Giovannetti E; Leon LG; Honeywell R; Peters GJ
    Curr Top Med Chem; 2012; 12(15):1649-59. PubMed ID: 22978339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors.
    Jimenez C; Cabanillas ME; Santarpia L; Jonasch E; Kyle KL; Lano EA; Matin SF; Nunez RF; Perrier ND; Phan A; Rich TA; Shah B; Williams MD; Waguespack SG
    J Clin Endocrinol Metab; 2009 Feb; 94(2):386-91. PubMed ID: 19017755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro.
    Bil J; Zapala L; Nowis D; Jakobisiak M; Golab J
    Cancer Lett; 2010 Feb; 288(1):57-67. PubMed ID: 19632769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
    Bagi CM; Gebhard DF; Andresen CJ
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
    Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
    Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines.
    Farsaci B; Donahue RN; Coplin MA; Grenga I; Lepone LM; Molinolo AA; Hodge JW
    Cancer Immunol Res; 2014 Nov; 2(11):1090-102. PubMed ID: 25092771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.